Multiple sclerosis and COVID‐19: How could therapeutic scenarios change during the pandemic?

We read with great interest the review by Rostami Mansoor and Ghasemi-Kasman entitled "Impact of disease-modifying drugs on the severity of coronavirus disease 2019 (COVID-19) infection in multiple sclerosis patients" in your journal.1 After examining the papers published on this topic, they conclude that it seems that disease-modifying drugs (DMTs) do not confer an increased risk or provoke COVID-19 infection in multiple sclerosis (MS) patients. Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic? Managing disease-modifying therapies and breakthrough activity in multiple sclerosis patients during the COVID-19 pandemic: toward an optimized approach. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. [Extracted from the article]